Hawaii Senate backs federal cannabis legalization with the recent passage of two pivotal resolutions, sending a clear message to Washington D.C. regarding the urgent need for comprehensive reform. Approved by a significant 20-5 margin on Thursday, April 10, 2026, these measures directly implore Congress to remove cannabis from the federal Controlled Substances Act, support state-level expungement efforts for past convictions, and crucially, facilitate access to full banking services for cannabis businesses operating legally under state law.
The resolutions, specifically SR58 and SCR64, underscore the inherent contradictions and economic impediments created by the federal government’s Schedule I classification of cannabis. Despite the growing number of states enacting their own cannabis policies, businesses, particularly medical cannabis dispensaries in Hawaii, remain vulnerable to federal enforcement actions including seizures, forfeitures, and arrests. This legal limbo stifles growth and innovation in an industry poised for significant economic impact.
Economic Imperatives for Federal Cannabis Legalization
The economic potential of a legal recreational cannabis industry in Hawaii is substantial, as highlighted by a state-commissioned study. This report projects sales exceeding $1 billion annually by its fifth year of operation, a figure that underscores the state’s vested interest in a stable and federally recognized market. However, current federal prohibitions severely limit this potential, particularly by denying cannabis-related businesses access to essential private banking services.
Senator Joy San Buenaventura (D), the primary sponsor of the resolutions, emphasized the dual impact of current federal policy. Beyond the economic constraints, she noted that “arrests and convictions for cannabis possession remain on record and often impact the ability of a person to obtain housing and employment.” This social justice aspect is a core component of the resolutions’ call for federal support for record-clearing initiatives, aiming to rectify historical harms inflicted by cannabis prohibition.
The legislative journey of these resolutions saw some notable amendments. The Senate Judiciary Committee, chaired by Sen. Karl Rhoads (D), opted to remove language that drew comparisons between cannabis and substances like alcohol and tobacco. Rhoads deemed these comparisons “irrelevant” to the core arguments for cannabis reform, streamlining the resolutions’ focus on federal policy changes.
Broader Policy Landscape and What’s Next
The passage of SCR64 means it now advances to the House of Representatives for consideration, while SR58, as a Senate resolution, represents the sentiment of that body and requires no further action. Should the House approve SCR64, both resolutions will be formally transmitted to President Donald Trump, Vice President JD Vance, and key congressional leaders, as well as Hawaii’s congressional delegation. This direct appeal to federal leadership signifies a coordinated effort from the state to influence national policy.
This push for federal reform comes amid a complex and often frustrating state-level legislative environment for cannabis in Hawaii. While the Senate recently approved a bill for limited low-dose and low-potency marijuana legalization, it ultimately failed to meet key deadlines, effectively dying for the year. Similarly, other legalization efforts and measures to regulate hemp-derived cannabinoid products were deferred, illustrating the challenges of achieving comprehensive reform at the state level without federal clarity.
“Even though states have made significant policy changes with respect to cannabis, the federal Controlled Substances Act still classifies cannabis as a Schedule I substance, which means that medical cannabis dispensaries and other cannabis-related businesses continue to face the prospect of federal seizures, forfeitures, arrests, and other enforcement and prosecution actions.”
Beyond the direct call for federal cannabis legalization, Hawaii’s legislature is also exploring other avenues related to drug policy. The Senate Health and Human Services Committee recently adopted separate resolutions urging the state attorney general and health department to seek an exemption from the Drug Enforcement Administration (DEA), aiming to protect Hawaii’s medical cannabis program from federal interference. Additionally, a bill to create a psychedelics task force to study and recommend policies for therapies like psilocybin and MDMA has advanced, signaling a broader legislative interest in alternative treatments and drug policy reform. Legislation allowing patients immediate access to medical cannabis upon registration and enabling its use in health facilities has also seen progress this session. For more on national trends in drug policy reform, readers can explore our related politics & policy articles.
The Hawaii Senate’s decisive vote for federal cannabis legalization underscores a growing impatience among states with the federal government’s outdated stance. By directly confronting the Schedule I classification and its multifaceted implications – from economic stagnation to social injustice – Hawaii is not merely advocating for its own interests but contributing to a national chorus demanding a rational and equitable approach to cannabis policy. The resolutions serve as a potent symbol of states’ rights and economic pragmatism, forcing federal policymakers to reckon with the realities of a rapidly evolving landscape.
